Latest Healthcare Research Reports

Tag: chronic plaque psoriasis market demand

  • Chronic Plaque Psoriasis Market Expected To Reach $30.99 Billion By 2030 As Growth Accelerates At 6.8% CAGR

    Chronic Plaque Psoriasis Market Expected To Reach $30.99 Billion By 2030 As Growth Accelerates At 6.8% CAGR

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Chronic Plaque Psoriasis Market Size, Value And Growth Trends Through 2030

    The global market for chronic plaque psoriasis experienced robust expansion lately, projected to advance from $22.26 billion in 2025 to $23.83 billion in 2026, reflecting a compound annual growth rate of 7.1%. This historical growth trajectory was fueled by enhanced identification of autoimmune skin conditions, greater accessibility to topical treatments, heightened understanding of psoriasis management strategies, an increase in dermatology centers, and improved access to specialized pharmaceutical options.

    The market for chronic plaque psoriasis is projected for substantial expansion in the upcoming years, anticipating a reach of $30.99 billion by 2030, reflecting a compound annual growth rate of 6.8%. This anticipated growth trajectory is fueled by several key factors including the accelerated development of advanced biologics, a greater uptake of oral immunomodulatory agents, the proliferation of precision dermatology methodologies, an elevated emphasis on treatment strategies centered around the patient, and increased financial backing for autoimmune disease investigations. Furthermore, within this forecast period, significant market dynamics will be shaped by the expanding utilization of biologic therapies, a surge in the application of targeted small molecule pharmaceuticals, a heightened focus on bespoke dermatological care, the broadening availability of oral treatment modalities, and an intensified commitment to achieving enduring disease management.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    Chronic Plaque Psoriasis Market Growth Drivers: What Factors Are Accelerating Expansion?

    The chronic plaque psoriasis market is poised for expansion due to a surge in immune system malfunctions. Such dysfunctions occur when the body’s natural defenses operate improperly, making individuals more vulnerable to illnesses including infections, autoimmune conditions, and cancers. Contributing factors to this rise in immune system issues include inherited traits, environmental influences, inadequate nutrition, persistent stress, and a growing incidence of conditions like HIV and other autoimmune disorders. Managing chronic plaque psoriasis becomes crucial for addressing these immune system irregularities, as an overzealous immune response can lead to accelerated skin cell production, resulting in inflammation and the characteristic plaque formations. For illustration, as of February 2024, Arthritis Australia reported projections indicating that in 2025, approximately 212,136 males and 362,137 females will be affected by rheumatoid arthritis, with anticipations for these figures to ascend by 2040 to roughly 280,040 males and 479,828 females. Consequently, the escalating prevalence of immune system disorders is directly fueling the advancement of the chronic plaque psoriasis market.

    Chronic Plaque Psoriasis Market Segment Analysis Highlighting Growth Areas

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

    Chronic Plaque Psoriasis Market Trends: What Is Shaping Future Industry Growth?

    Key players within the chronic plaque psoriasis market are concentrating their efforts on pioneering therapeutic solutions, including IL-17A and IL-17F inhibitors, aiming to achieve progress in managing chronic plaque psoriasis. Therapies that specifically target IL-17A and IL-17F function by intercepting these pro-inflammatory cytokines, which are integral to the immune system’s response, thereby diminishing inflammation associated with autoimmune conditions like chronic plaque psoriasis. A significant development occurred in October 2023 when UCB S.A., a biopharmaceutical firm based in Belgium, revealed that the U.S. Food and Drug Administration (FDA) had granted approval for BIMZELX (bimekizumab-bkzx) to treat adult patients experiencing moderate to severe plaque psoriasis who are candidates for systemic or phototherapy. Bimekizumab stands out as the inaugural approved therapy for psoriasis engineered to specifically target and inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial cytokines implicated in inflammatory pathways. This approval was substantiated by findings from three main Phase 3 studies—BE READY, BE VIVID, and BE SURE—which collectively evaluated the safety and effectiveness of bimekizumab in a cohort of 1,480 individuals diagnosed with moderate to severe plaque psoriasis.

    Chronic Plaque Psoriasis Market Leading Companies: Who Holds Significant Market Presence?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol‑Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio‑Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

    Access The Complete Chronic Plaque Psoriasis Market Report:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Chronic Plaque Psoriasis Market Regional Analysis And Leading Geography

    North Americawas the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand Is Supporting Development Across The Chronic Plaque Psoriasis Market

    Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand Is Supporting Development Across The Chronic Plaque Psoriasis Market

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    By 2030, How Much Growth In Market Size Is Expected For The Chronic Plaque Psoriasis Market?

    The chronic plaque psoriasis market has experienced strong expansion in recent years. It is forecast to grow from $22.26 billion in 2025 to $23.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The historical increase in this market can be attributed to an improved diagnosis of autoimmune skin disorders, the wider availability of topical therapies, a heightened awareness of psoriasis management, the expansion of dermatology clinics, and enhanced access to specialty drugs.

    The chronic plaque psoriasis market is expected to witness significant expansion in the upcoming years. It is projected to achieve a size of $30.99 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. The projected increase in this period stems from the accelerated development of next-generation biologics, the increasing use of oral immunomodulators, the expansion of precision dermatology techniques, a heightened focus on patient-centric treatment approaches, and increased funding in autoimmune disease research. Notable trends for the forecast period include the growing acceptance of biologic therapies, a rise in the application of targeted small molecule drugs, an increasing emphasis on individualized dermatology care, the broadening availability of oral treatment choices, and a stronger focus on sustained disease management.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    Which Growth Drivers Are Expected To Support The Chronic Plaque Psoriasis Market Forward?

    The future expansion of the chronic plaque psoriasis market is anticipated to be driven by the rising occurrence of immune system dysfunction. Immune system dysfunction refers to a state where the immune system fails to operate effectively, leading to increased susceptibility to infections, autoimmune diseases, and cancer. This growth in immune system dysfunction cases is attributed to factors such as genetic predispositions, environmental triggers, malnutrition, chronic stress, and the escalating prevalence of autoimmune diseases and infections like HIV. Chronic plaque psoriasis treatment is essential for regulating immune system dysfunction, as the immune system mistakenly triggers an overproduction of skin cells, resulting in inflammation and the formation of plaques. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these numbers expected to increase by 2040 to approximately 280,040 males and 479,828 females. Consequently, the increasing cases of immune system dysfunction are fueling the growth of the chronic plaque psoriasis market.

    How Is The Chronic Plaque Psoriasis Market Structured Across Different Market Segments?

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

    Which Trends Are Guiding The Development Of The Chronic Plaque Psoriasis Market?

    Leading companies within the chronic plaque psoriasis market are concentrating on creating advanced therapies, including IL-17A and IL-17F inhibitors, aiming to improve treatment options for the condition. These inhibitors are specific biologic drugs designed to obstruct interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines contributing to the immune response, thereby lessening inflammation in autoimmune conditions such as chronic plaque psoriasis. As an illustration, in October 2023, UCB S.A., a biopharmaceutical firm from Belgium, disclosed that BIMZELX (bimekizumab-bkzx) received approval from the U.S. Food and Drug Administration (FDA) for treating adults with moderate to severe plaque psoriasis who qualify for systemic or phototherapy treatments. Bimekizumab stands as the inaugural approved medication for psoriasis uniquely formulated to specifically target and suppress interleukin 17A (IL-17A) and interleukin 17F (IL-17F), critical cytokines central to inflammatory pathways. The approval of this drug stemmed from data collected across three Phase 3 multicenter trials, namely BE READY, BE VIVID, and BE SURE, which collectively evaluated its safety and effectiveness in 1,480 individuals suffering from moderate to severe plaque psoriasis.

    Which Organizations Are Involved In The Chronic Plaque Psoriasis Market?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

    Access The Complete Chronic Plaque Psoriasis Market Report:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Which Region Holds The Largest Share In The Chronic Plaque Psoriasis Market?

    North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Chronic Plaque Psoriasis Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

    Pancreatic Cancer Diagnostic Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

    Exocrine Pancreatic Insufficiency Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

    Invasive Ductal Carcinoma Therapeutics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chronic Plaque Psoriasis Market (2026–2030): Innovation and Competitive Landscape

    Chronic Plaque Psoriasis Market (2026–2030): Innovation and Competitive Landscape

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Does The Market Size Of The Chronic Plaque Psoriasis Market Compare Between 2026 And 2030?

    The chronic plaque psoriasis market has shown strong growth recently. It is anticipated to expand from $22.26 billion in 2025 to $23.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical increase is due to improved diagnosis of autoimmune skin disorders, wider availability of topical therapies, increased awareness of psoriasis management, expansion of dermatology clinics, and improved access to specialty drugs.

    The chronic plaque psoriasis market is forecast to experience substantial growth in the upcoming years. Its size is expected to increase to $30.99 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.8%. This expansion during the forecast period can be attributed to the rising development of next-generation biologics, increased adoption of oral immunomodulators, the broadening of precision dermatology approaches, a growing focus on patient-centric treatment strategies, and intensified investment in autoimmune disease research. Significant trends anticipated during this period include an elevated uptake of biologic therapies, a rise in the use of targeted small molecule drugs, a greater emphasis on personalized dermatology care, an expansion of available oral treatment options, and an enhanced focus on long-term disease management.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    What Significant Factors Are Influencing The Chronic Plaque Psoriasis Market Expansion?

    The rising incidence of immune system dysfunction is anticipated to drive the expansion of the chronic plaque psoriasis market in the future. This condition denotes a state where the immune system does not function optimally, consequently heightening vulnerability to infections, autoimmune disorders, and various cancers. The surge in immune system dysfunction cases is linked to factors including genetic predispositions, environmental stimuli, nutritional deficiencies, persistent stress, and the increasing occurrence of autoimmune diseases and infections such as HIV. Management of immune system dysfunction often necessitates chronic plaque psoriasis treatment, as the immune system’s erroneous activation leads to an excessive proliferation of skin cells, resulting in inflammation and the development of plaques. For example, in February 2024, data from Arthritis Australia, an Australia-based non-profit organization, indicated that an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these figures anticipated to climb by 2040 to approximately 280,040 males and 479,828 females. Thus, the expanding prevalence of immune system dysfunction is a key force propelling the growth of the chronic plaque psoriasis market.

    Which Segment Types Are Examined In The Chronic Plaque Psoriasis Market Segment Study?

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

    What Trends Are Affecting The Direction Of The Chronic Plaque Psoriasis Market?

    Leading companies in the chronic plaque psoriasis market are concentrating on developing advanced treatments, such as IL-17A and IL-17F inhibitors, to improve therapy for chronic plaque psoriasis. These IL-17A and IL-17F inhibitors are targeted biologic therapies that work by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, thereby reducing inflammation in autoimmune conditions like chronic plaque psoriasis. For example, in October 2023, UCB S.A., a biopharmaceutical company based in Belgium, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the initial approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two critical cytokines in inflammatory processes. Its approval was supported by evidence from three Phase 3 multicenter trials, namely BE READY, BE VIVID, and BE SURE, which collectively assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

    Which Players Are Part Of The Competitive Landscape Of The Chronic Plaque Psoriasis Market?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

    Get The Full Chronic Plaque Psoriasis Market Report:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Which Region Is The Top Contributor To The Chronic Plaque Psoriasis Market By Share?

    North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Chronic Plaque Psoriasis Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

    Rheumatology Therapeutics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

    Chronic Spontaneous Urticaria Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

    Veterinary Dermatology Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chronic Plaque Psoriasis Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    Chronic Plaque Psoriasis Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Will The Market Size Of The Chronic Plaque Psoriasis Market Evolve From 2026 To 2030?

    The market size for chronic plaque psoriasis has demonstrated substantial growth over recent years. Projections indicate an increase from $22.26 billion in 2025 to $23.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. Historically, this market expansion can be attributed to several factors including improved diagnosis of autoimmune skin disorders, wider availability of topical therapies, increased awareness of psoriasis management, expansion of dermatology clinics, and improved access to specialty drugs.

    The chronic plaque psoriasis market is projected to experience substantial expansion over the upcoming years. By 2030, its size is anticipated to reach $30.99 billion, exhibiting a compound annual growth rate (CAGR) of 6.8%. This projected growth during the forecast period stems from factors such as the accelerated development of next-generation biologics, the increasing embrace of oral immunomodulators, the broader application of precision dermatology strategies, a heightened emphasis on patient-centric treatment approaches, and a greater commitment to investment in autoimmune disease research. Key trends anticipated within the forecast period encompass a surge in the adoption of biologic therapies, an increased utilization of targeted small molecule drugs, a strengthening focus on personalized dermatology care, an expansion in available oral treatment options, and a reinforced commitment to achieving long-term disease control.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    What Key Drivers Are Influencing The Growth Of The Chronic Plaque Psoriasis Market?

    The expanding incidence of immune system dysfunction is anticipated to fuel the future expansion of the chronic plaque psoriasis market. Immune system dysfunction describes a condition where the immune system does not function properly, increasing vulnerability to infections, autoimmune disorders, and cancer. A growing number of immune system dysfunction cases stem from factors like genetic susceptibility, environmental irritants, poor nutrition, prolonged stress, and the increasing occurrence of autoimmune conditions and infections such as HIV. Treatment for chronic plaque psoriasis is necessary to manage immune system dysfunction, given that the immune system erroneously stimulates excessive skin cell production, resulting in inflammation and plaque development. For example, as reported in February 2024 by Arthritis Australia, an Australia-based non-profit organization, in 2025, approximately 212,136 males and 362,137 females are estimated to be affected by rheumatoid arthritis (RA), with these figures anticipated to climb by 2040 to around 280,040 males and 479,828 females. Consequently, the rising instances of immune system dysfunction are fueling the expansion of the chronic plaque psoriasis market.

    Which Segment Areas Are Covered In The Chronic Plaque Psoriasis Market Analysis?

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

    How Are Trends Transforming The Chronic Plaque Psoriasis Market Landscape?

    Major companies in the chronic plaque psoriasis market are prioritizing the development of innovative treatments, such as IL-17A and IL-17F inhibitors, to enhance therapeutic options for chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that work by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, thereby reducing inflammation in autoimmune diseases like chronic plaque psoriasis. For instance, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. Bimekizumab is the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines implicated in inflammatory processes. Its approval was founded on data from three Phase 3 multicenter trials—BE READY, BE VIVID, and BE SURE—which together assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

    Which Global Companies Are Actively Competing In The Chronic Plaque Psoriasis Market?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

    Read the full chronic plaque psoriasis market report here:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Which Region Is Expected To Register The Fastest Growth In The Chronic Plaque Psoriasis Market?

    North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Chronic Plaque Psoriasis Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

    Pancreatic Cancer Diagnostic Global Market Report

    https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

    Exocrine Pancreatic Insufficiency Global Market Report

    https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

    Invasive Ductal Carcinoma Therapeutics Global Market Report

    https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Chronic Plaque Psoriasis Market Report 2026: Emerging Trends and Growth Scenarios

    Global Chronic Plaque Psoriasis Market Report 2026: Emerging Trends and Growth Scenarios

    Uncover key drivers, emerging technologies, and competitive movements shaping the chronic plaque psoriasis market from 2026–2035 with trusted insights from The Business Research Company

    What is the estimated market size of the Chronic Plaque Psoriasis Market by the end of 2030?

    The market for chronic plaque psoriasis has experienced significant expansion recently. It is projected to increase from $22.26 billion in 2025 to $23.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.1%. Historically, this growth has been driven by factors such as enhanced diagnosis of autoimmune skin conditions, broader access to topical treatments, heightened public awareness concerning psoriasis management, the proliferation of dermatology clinics, and better availability of specialized medications.

    The chronic plaque psoriasis market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a value of $30.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This projected growth is driven by several factors, including the escalating development of advanced biologics, the increasing embrace of oral immunomodulators, the broader application of precision dermatology, a heightened emphasis on patient-centered care strategies, and boosted investments in autoimmune disease research. Key trends anticipated during this period involve the rising acceptance of biologic therapies, the increased utilization of targeted small molecule medications, a sharpened focus on individualized dermatological care, the proliferation of oral treatment alternatives, and a greater commitment to sustained disease management.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    What Drivers Are Shaping Future Opportunities In The Chronic Plaque Psoriasis Market?

    The future expansion of the chronic plaque psoriasis market is anticipated to be driven by the rising incidence of immune system dysfunction. This dysfunction describes a condition where the immune system fails to function properly, making individuals more vulnerable to infections, autoimmune disorders, and cancer. Various elements, including genetic factors, environmental influences, poor nutrition, ongoing stress, and the growing occurrence of autoimmune conditions and infections such as HIV, contribute to the increasing instances of immune system dysfunction. Treatment for chronic plaque psoriasis is essential for managing immune system dysfunction, given that the immune system erroneously stimulates excessive skin cell production, resulting in inflammation and plaque formation. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that in 2025, approximately 212,136 males and 362,137 females are forecast to develop rheumatoid arthritis (RA). These figures are projected to increase by 2040, reaching an estimated 280,040 males and 479,828 females. Consequently, the expanding number of immune system dysfunction cases is propelling the growth of the chronic plaque psoriasis market.

    Which Segment Groups Are Influencing The Chronic Plaque Psoriasis Market?

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

    What Trends Are Driving The Growth Trajectory Of The Chronic Plaque Psoriasis Market?

    Major companies within the chronic plaque psoriasis market are concentrating on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to advance the therapeutic landscape for chronic plaque psoriasis. These IL-17A and IL-17F inhibitors function as targeted biologic therapies, blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, to diminish inflammation in autoimmune disorders like chronic plaque psoriasis. For example, in October 2023, UCB S.A., a biopharmaceutical company based in Belgium, announced that the U.S. Food and Drug Administration (FDA) had granted approval for BIMZELX (bimekizumab-bkzx) for use in adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Bimekizumab is notable as the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two significant cytokines implicated in inflammatory processes. Its approval was substantiated by evidence from three Phase 3 multicenter trials — BE READY, BE VIVID, and BE SURE — which collectively assessed its safety and efficacy in 1,480 patients suffering from moderate to severe plaque psoriasis.

    Who Are The Prominent Global Companies Shaping The Chronic Plaque Psoriasis Market Landscape?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Which Region Currently Holds The Largest Share Of The Chronic Plaque Psoriasis Market?

    North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Chronic Plaque Psoriasis Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

    Rheumatology Therapeutics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

    Chronic Spontaneous Urticaria Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

    Veterinary Dermatology Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chronic Plaque Psoriasis Market Size, Share & Trends Analysis Report By Product | Forecast to 2029

    Chronic Plaque Psoriasis Market Size, Share & Trends Analysis Report By Product | Forecast to 2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Are The Future Growth Projections For The Chronic Plaque Psoriasis Market Size?

    Over the last few years, the market size for chronic plaque psoriasis has seen robust growth. Projections suggest that it will increase from $20.79 billion in 2024, reaching $22.26 billion in 2025 – reflecting a compound annual growth rate (CAGR) of 7.0%. This historical period growth can be ascribed to the increasing instances of psoriasis, a rise in related co-morbidities, beneficial reimbursement policies, a surge in alcohol and smoking consumption, as well as the emergence of telemedicine.

    The market size for chronic plaque psoriasis is predicted to witness robust expansion in the upcoming years, hitting $29.09 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This growth during the forecast period is likely due to the increasing or decreasing incidence of cpp worldwide, the surge in autoimmune diseases, expansion in healthcare budgets, an aging demographic, and the growing demand for potent treatments. Key trends during this forecast timeframe include progress in biologic treatments, oral small molecule inhibitors, the integration of digital health, personalized medicine, and the introduction of biosimilars.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    Which Factors Are Steering Growth In The Chronic Plaque Psoriasis Market?

    The escalation in incidences of immune system malfunctions is anticipated to fuel the expansion of the market for chronic plaque psoriasis. The term refers to a scenario where the immune system ceases to function efficiently, leading to higher vulnerability to infections, autoimmune diseases, and cancer. The rise in such cases can be attributed to various aspects including genetic susceptibility, environmental triggers, malnutrition, chronic stress, and the escalating rate of autoimmune diseases and infections like HIV. Treating chronic plaque psoriasis is necessary to manage the malfunctioning immune system as it mistakenly promotes excess production of skin cells, triggering inflammation and plaque formation. For example, the National Psoriasis Foundation, a non-profit organization from the US, reported in December 2022 that over 8 million Americans suffer from psoriasis. On an international scale, this condition impacts 125 million individuals, representing 2 to 3% of the global population. Therefore, the rise in immune system dysfunctions is steering the expansion of the chronic plaque psoriasis market.

    How Is The Chronic Plaque Psoriasis Market Organized By Different Segments?

    The chronic plaque psoriasismarket covered in this report is segmented –

    1) By Drug Class: Biologics; Small Molecule Drugs

    2) By Route Of Administration: Injectable; Oral; Topical

    3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others

    What Current And Upcoming Trends Are Shaping The Chronic Plaque Psoriasis Market?

    Premier businesses in the chronic plaque psoriasis market are striving to develop innovative therapeutics, such as IL-17A and IL-17F inhibitors, to improve the treatment methodology for chronic plaque psoriasis. IL-17A and IL-17F inhibitors are specifically designed biologic treatments that aim to hinder interleukin-17A and interleukin-17F, pro-inflammatory cytokines associated with the immune response, in order to minimize inflammation in autoimmune diseases like chronic plaque psoriasis. For example, UCB S.A., a Belgium-based biopharmaceutical firm, disclosed in October 2023, that U.S. Food and Drug Administration (FDA) granted approval for BIMZELX (bimekizumab-bkzx) to be used by adults with moderate to severe plaque psoriasis who qualify for systemic therapy or phototherapy. Bimekizumab is a unique medication designed specifically for psoriasis that targets and impedes interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two significant cytokines involved in inflammation. This approval was supported by evidence from three Phase 3 trials—BE READY, BE VIVID, and BE SURE—that evaluated its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

    Who Are The Most Influential Companies In The Chronic Plaque Psoriasis Market?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Which Region Dominates The Chronic Plaque Psoriasis Market Today?

    North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2025, By The Business Research Company

    Psoriasis Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

    Autoimmune Disease Diagnosis Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

    Granulocyte Colony Stimulating Factors Market 2025

    https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Key Factors Fueling the Growth of the Chronic Plaque Psoriasis Market in 2025: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand

    Key Factors Fueling the Growth of the Chronic Plaque Psoriasis Market in 2025: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Key Projections for the CAGR of the Chronic Plaque Psoriasis Market Size From 2025 to 2034?

    The market size for chronic plaque psoriasis has seen robust growth over the past several years. It is projected to expand from a value of $20.79 billion in 2024 to $22.26 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.0%. Factors such as the increasing prevalence of psoriasis, a surge in co-morbidities, beneficial insurance reimbursement policies, raised levels of alcohol and tobacco use, along with the emergence of telemedicine, all contribute to the substantial growth observed in the historic period.

    Anticipations of significant expansion are being made for the chronic plaque psoriasis market in the near future, with a projected growth to reach a hefty$29.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.9%. The expected growth during this forecast period can be tied to the increasing or decreasing occurrences of cpp globally, a rise in autoimmune diseases, an expansion in healthcare budgets, an aging demographic, and a growing demand for effective treatments. Key trends projected to emerge during this period comprise of progress in biologic treatments, the introduction of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the launch of biosimilars.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    What are the Fundamental Drivers and Innovations Shaping the Chronic Plaque Psoriasis Market?

    The escalation in instances of immune system dysregulation is predicted to boost the chronic plaque psoriasis market’s expansion. The term immune system dysregulation denotes a condition when the immune system doesn’t function optimally, resulting in a heightened vulnerability to infections, autoimmune diseases, and cancer. This increase in immune system dysfunctions is accredited to factors such as genetic factors, environmental influences, malnutrition, persistent stress, and the growing incidents of autoimmune diseases and infections like HIV. Treatment for chronic plaque psoriasis is necessary to control immune system dysfunctions as the immune system incorrectly instigates an excess production of skin cells, causing inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, an American nonprofit organization, disclosed that over 8 million Americans are plagued with psoriasis. On a global scale, this condition affects 125 million individuals, making up 2 to 3% of the total population. Hence, the escalating instances of immune system dysfunction are contributing to the growth of the chronic plaque psoriasis market.

    How Is the Chronic Plaque Psoriasis Market Segmented?

    The chronic plaque psoriasismarket covered in this report is segmented –

    1) By Drug Class: Biologics; Small Molecule Drugs

    2) By Route Of Administration: Injectable; Oral; Topical

    3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Which Regions Are Driving the Next Phase of the Chronic Plaque Psoriasis Market Growth?

    North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Key Trends Are Shaping the Future of the Chronic Plaque Psoriasis Market?

    Leading companies within the chronic plaque psoriasis market are directing their efforts towards devising novel therapies, specifically IL-17A and IL-17F inhibitors, aiming at enhancing the treatment process for this condition. These suppressive biological treatments function by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines that play a significant role in immune responses, thereby mitigating inflammation associated with autoimmune disorders like chronic plaque psoriasis. An exemplar case of this occurred in October 2023 when UCB S.A., a biopharmaceutical corporation situated in Belgium, disclosed that BIMZELX (bimekizumab-bkzx) had received approval from the U.S. Food and Drug Administration (FDA). This authorization was for its use in treating adults suffering from moderate to extreme plaque psoriasis and who are suitable candidates for systemic therapy or phototherapy. Bimekizumab sets a new precedent as the premier psoriasis medication specifically created to inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), both integral cytokines in inflammatory reactions. The FDA’s endorsement was grounded on data procured from three Phase 3 multicenter studies, labeled as BE READY, BE VIVID, and BE SURE. These trials undertook a comprehensive evaluation of its safety profile and efficacy among 1,480 patients diagnosed with moderate-to-severe plaque psoriasis.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    How Is the Chronic Plaque Psoriasis Market Defined and What Are Its Core Parameters?

    Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Key Factors Fueling the Growth of the Chronic Plaque Psoriasis Market in 2025: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand

    Key Factors Fueling the Growth of the Chronic Plaque Psoriasis Market in 2025: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Key Projections for the CAGR of the Chronic Plaque Psoriasis Market Size From 2025 to 2034?

    The market size for chronic plaque psoriasis has seen robust growth over the past several years. It is projected to expand from a value of $20.79 billion in 2024 to $22.26 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.0%. Factors such as the increasing prevalence of psoriasis, a surge in co-morbidities, beneficial insurance reimbursement policies, raised levels of alcohol and tobacco use, along with the emergence of telemedicine, all contribute to the substantial growth observed in the historic period.

    Anticipations of significant expansion are being made for the chronic plaque psoriasis market in the near future, with a projected growth to reach a hefty$29.09 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.9%. The expected growth during this forecast period can be tied to the increasing or decreasing occurrences of cpp globally, a rise in autoimmune diseases, an expansion in healthcare budgets, an aging demographic, and a growing demand for effective treatments. Key trends projected to emerge during this period comprise of progress in biologic treatments, the introduction of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the launch of biosimilars.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    What are the Fundamental Drivers and Innovations Shaping the Chronic Plaque Psoriasis Market?

    The escalation in instances of immune system dysregulation is predicted to boost the chronic plaque psoriasis market’s expansion. The term immune system dysregulation denotes a condition when the immune system doesn’t function optimally, resulting in a heightened vulnerability to infections, autoimmune diseases, and cancer. This increase in immune system dysfunctions is accredited to factors such as genetic factors, environmental influences, malnutrition, persistent stress, and the growing incidents of autoimmune diseases and infections like HIV. Treatment for chronic plaque psoriasis is necessary to control immune system dysfunctions as the immune system incorrectly instigates an excess production of skin cells, causing inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, an American nonprofit organization, disclosed that over 8 million Americans are plagued with psoriasis. On a global scale, this condition affects 125 million individuals, making up 2 to 3% of the total population. Hence, the escalating instances of immune system dysfunction are contributing to the growth of the chronic plaque psoriasis market.

    How Is the Chronic Plaque Psoriasis Market Segmented?

    The chronic plaque psoriasismarket covered in this report is segmented –

    1) By Drug Class: Biologics; Small Molecule Drugs

    2) By Route Of Administration: Injectable; Oral; Topical

    3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Which Regions Are Driving the Next Phase of the Chronic Plaque Psoriasis Market Growth?

    North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Key Trends Are Shaping the Future of the Chronic Plaque Psoriasis Market?

    Leading companies within the chronic plaque psoriasis market are directing their efforts towards devising novel therapies, specifically IL-17A and IL-17F inhibitors, aiming at enhancing the treatment process for this condition. These suppressive biological treatments function by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines that play a significant role in immune responses, thereby mitigating inflammation associated with autoimmune disorders like chronic plaque psoriasis. An exemplar case of this occurred in October 2023 when UCB S.A., a biopharmaceutical corporation situated in Belgium, disclosed that BIMZELX (bimekizumab-bkzx) had received approval from the U.S. Food and Drug Administration (FDA). This authorization was for its use in treating adults suffering from moderate to extreme plaque psoriasis and who are suitable candidates for systemic therapy or phototherapy. Bimekizumab sets a new precedent as the premier psoriasis medication specifically created to inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), both integral cytokines in inflammatory reactions. The FDA’s endorsement was grounded on data procured from three Phase 3 multicenter studies, labeled as BE READY, BE VIVID, and BE SURE. These trials undertook a comprehensive evaluation of its safety profile and efficacy among 1,480 patients diagnosed with moderate-to-severe plaque psoriasis.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    How Is the Chronic Plaque Psoriasis Market Defined and What Are Its Core Parameters?

    Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chronic Plaque Psoriasis Market to Reach $29.33 Billion by 2029 | Key Drivers and Future Outlook

    Chronic Plaque Psoriasis Market to Reach $29.33 Billion by 2029 | Key Drivers and Future Outlook

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Chronic Plaque Psoriasis Market?

    In recent years, there has been a robust growth in the chronic plaque psoriasis market. The market, valued at $20.79 billion in 2024, is projected to expand to $22.32 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%. The notable growth during the historical period is attributable to factors such as an increasing number of psoriasis cases, rising incidences of related conditions, positive reimbursement policies, escalating consumption of alcohol and smoking, and the emergence of telemedicine.

    What Growth Rate Is Forecasted for the Chronic Plaque Psoriasis Market by 2029?

    The size of the chronic plaque psoriasis market is predicted to experience significant expansion in the forthcoming years, reaching $29.33 billion by 2029 with a 7.1% compound annual growth rate (CAGR). The anticipated growth during the forecast period is primarily due to rising or falling occurrence rates of cpp globally, an upsurge in autoimmune diseases, expanded healthcare budgets, an aging demography, and escalating demands for efficacious treatments. Prevailing trends that will shape the forecast period comprise breakthroughs in biologic treatments, the emergence of oral small molecule inhibitors, integration of digital health technologies, personalizing medication, and the advent of biosimilars.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    Which Key Companies Are Shaping the Future of the Chronic Plaque Psoriasis Market?

    Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy’s Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

    Which Factors Are Driving Demand in the Chronic Plaque Psoriasis Industry?

    The rise in instances of dysfunction in the immune system is anticipated to stimulate the expansion of the chronic plaque psoriasis market. This dysfunction, wherein the immune system’s proper functioning is compromised, thereby making individuals more vulnerable to infections, autoimmune diseases, and cancer, can be attributed to elements such as genetic predispositions, environmental triggers, and a lack of proper nutrition, chronic stress, and a surge in prevalence of autoimmune diseases and infections such as HIV. The treatment of chronic plaque psoriasis is critical to managing this immune system dysfunction, as an erring immune system could lead to overproduction of skin cells resulting in inflammation and plaque formation. For instance, the National Psoriasis Foundation, a not-for-profit organization based in the US, stated in December 2022 that psoriasis affects over 8 million Americans. Around the world, the condition affects 125 million individuals, accounting for 2 to 3% of the global population. As a result, the escalating number of instances of immune system dysfunction is fueling the surge in demand in the chronic plaque psoriasis market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    How Is the Chronic Plaque Psoriasis Market Segmented by Several Divisions?

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

    What are the Emerging Market Trends Driving the Growth of the Chronic Plaque Psoriasis Industry?

    Leading corporations in the chronic plaque psoriasis industry are centering their efforts on the creation of innovative solutions such as IL-17A and IL-17F inhibitors in a bid to progress treatment options in this field. These inhibitors function as targeted biologic treatments that inhibit interleukin-17A and interleukin-17F, cytokines responsible for inflaming autoimmune diseases like chronic plaque psoriasis. To illustrate, UCB S.A., a biopharmaceutical firm from Belgium, revealed in October 2023 that their drug BIMZELX (bimekizumab-bkzx) received approval from the U.S. Food and Drug Administration (FDA) for usage in adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. As the first medication developed specifically to target and block interleukin 17A (IL-17A) and interleukin 17F (IL-17F), Bimekizumab is a breakthrough in managing psoriasis. This FDA approval is backed by evidence gathered from three multicenter Phase 3 studies—BE READY, BE VIVID, and BE SURE—which collectively evaluated its safety and efficacy in 1,480 patients suffering from moderate to severe plaque psoriasis.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    Which Regions Are Driving Growth in the Chronic Plaque Psoriasis Market?

    North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

    This Report Delivers Insight On:

    1. How big is the chronic plaque psoriasis market, and how is it changing globally?

    2. Who are the major companies in the chronic plaque psoriasis market, and how are they performing?

    3. What are the key opportunities and risks in the chronic plaque psoriasis market right now?

    4. Which products or customer segments are growing the most in the chronic plaque psoriasis market?

    5. What factors are helping or slowing down the growth of the chronic plaque psoriasis market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Major Drivers Propelling the Growth oh theChronic Plaque Psoriasis Market Forward: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand

    Major Drivers Propelling the Growth oh theChronic Plaque Psoriasis Market Forward: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand

    Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

    How Fast Is The Chronic Plaque Psoriasis Market Expected to Grow Between 2025 And 2029?

    The market size for chronic plaque psoriasis has seen significant growth in the past few years. The projection suggests an increase from $20.79 billion in 2024 to $22.32 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 7.3%. The upward trend during the historic phase can be linked to factors such as an increased number of psoriasis cases, higher rates of co-morbidities, beneficial reimbursement policies, a surge in alcohol and tobacco use, and the emergence of telemedicine.

    In the upcoming years, the market size for chronic plaque psoriasis is projected to experience robust growth, eventually reaching $29.33 billion at a compound annual growth rate (CAGR) of 7.1% by 2029. This growth during the projected period is attributable to various factors such as an increase or decrease in global cpp prevalence, the surge in autoimmune diseases, augmentation in healthcare budgets, the aging population, and a rising demand for effective treatments. Noticeable trends during this period involve advancements in biologic treatments, the emergence of oral small molecule inhibitors, the integration of digital health, personalized medicine, and the introduction of biosimilars.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Plaque Psoriasis Market?

    The rise in immune system dysfunction cases is projected to fuel the expansion of the chronic plaque psoriasis market. This condition occurs when the immune system does not perform efficiently, resulting in a heightened risk of infections, autoimmune diseases, and cancer. A multitude of factors such as genetic predispositions, environmental factors, malnutrition, chronic stress, and the increasing occurrence of autoimmune diseases and infections like HIV are believed to contribute to this increase in immune system dysfunction. Treatment for chronic plaque psoriasis is crucial in managing this dysfunction, as the immune system erroneously stimulates an overproduction of skin cells, causing inflammation and plaque formation. For instance, in December 2022, the National Psoriasis Foundation, a nonprofit organization based in the US, stated that over 8 million Americans battle with psoriasis. This condition affects 125 million people worldwide, which represents 2 to 3% of the global population. Consequently, the escalating cases of immune system dysfunction are spurring the chronic plaque psoriasis market’s growth.

    Which Key Market Segments Comprise the Chronic Plaque Psoriasis Market and Drive Its Revenue Growth?

    The chronic plaque psoriasis market covered in this report is segmented –

    1) By Drug Class: Biologics, Small Molecule Drugs

    2) By Route Of Administration: Injectable, Oral, Topical

    3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

    Subsegments:

    1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others

    2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

    Which Areas Are Leading Regions in the Chronic Plaque Psoriasis Market Expansion Across the Globe?

    North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Key Market Trends in the Chronic Plaque Psoriasis Market Over the Coming Years?

    The chief businesses active in the chronic plaque psoriasis market are channeling their efforts into creating novel treatments, such as IL-17A and IL-17F inhibitors. These innovations aim to improve the treatment process of chronic plaque psoriasis. IL-17A and IL-17F inhibitors are specialized biological treatments that obstruct interleukin-17A and interleukin-17F. These inflammation-causing cytokines contribute to the immune response, and their inhibition results in decreases inflammation in autoimmune disorders like chronic plaque psoriasis. As an illustration, in October 2023, UCB S.A., a biopharmaceutical firm based in Belgium, announced that the US Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for use in adults diagnosed with moderate to severe plaque psoriasis who qualify for systemic therapy or phototherapy. Bimekizumab, which specifically targets and blocks interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial inflammation-causing cytokines, was the first medication approved for psoriasis. The drug’s approval was based on evidence derived from three multicenter Phase 3 trials—BE READY, BE VIVID, and BE SURE—which collectively examined its safety and effectiveness in treating 1,480 patients with moderate to severe plaque psoriasis.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

    How Is the Chronic Plaque Psoriasis Market Conceptually Defined?

    Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model